Gilead’s $5B Tubulis Deal Validates ADC Space – Bullish for Sutro Biopharma
Leerink sees major tailwind for Sutro Biopharma and initiates coverage with $38 price target.
/ 1659 items
#XY↓
Perrigo Stock Jumps on Takeover Rumors from German Drugmaker Stada
Perrigo Co. stock rose on takeover rumors, possibly by Stada Arzneimittel AG. No deal confirmed yet.
Gilead’s Third Deal of 2026: $3.15B Buyout of ADC Specialist Tubulis
Gilead buys German biotech Tubulis for $3.15B to boost cancer-fighting “smart” drugs called ADCs. Deal closes Q2 2026.
FDA Gives Fast Track Boost to Climb Bio’s Budoprutug for Primary Membranous Nephropathy
Climb Bio stock jumps after FDA fast-track for budoprutug, a new drug for rare kidney disease pMN.
AC Immune & Lilly Team Up Again to Stop Alzheimer’s with Brain-Targeting Drugs
AC Immune updates Eli Lilly deal to develop pill-based Tau drugs for Alzheimer’s, aiming to stop disease early with promising preclinical results.
Bio-Rad Faces Headwinds as Citi Downgrades Shares to Neutral
Citi downgrades Bio-Rad to Neutral, citing weak chromatography growth and China market risks; price target cut to $300.